All In Biotech

Drug Trial Radar · NCT06810245

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Crossover Multicenter Study to Explore the Safety and Efficacy of Oral PIPE-791 as Treatment in Subjects With Chronic Osteoarthritis Pain (COAP) or Chronic Low Back Pain (CLBP)

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Feb 4, 2025

Primary completion

Jan 20, 2026

Study completion Jan 20, 2026

Sponsor

Lead sponsor
Contineum TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP. Subjects will: * Complete a washout period to stop their current pain medications. * Take a daily dose of PIPE-791 or placebo for 4 weeks, then reverse treatment assignment for another 4 weeks. * Record pain levels and track dosing in a daily e-diary. * Visit the clinic for checkups and lab tests throughout the study. * Complete phone assessments during the treatment periods.

Conditions

  • Chronic Osteoarthritis Pain
  • Chronic Low Back Pain

Interventions

  • PIPE-791Drug

    PIPE-791 tablet, taken once daily for 4 weeks

  • PlaceboDrug

    Placebo tablet, taken once daily for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with Treatment-emergent adverse events (TEAEs)Time frame: For Treatment Period 1, from Baseline (Day 1) to End of Treatment Period 1 (TP1; Day 29), for Treatment Period 2, from Baseline of Treatment Period 2 (TP2; Day 29) to End of TP2 (Day 57).

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Research Center

    Phoenix, Arizona

  • Drug Studies America

    Marietta, Georgia

  • Drug Trials America

    Hartsdale, New York

  • Altoona Center of Clinical Research

    Duncansville, Pennsylvania

  • JBR Clinical Research

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.